Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.
Mark J. Levis(Sidney Kimmel Cancer Center), B. Douglas Smith(Johns Hopkins University), Steven Coutré(Georgetown University), Robert K. Stuart(Memorial Sloan Kettering Cancer Center), Larry D. Cripe(Indiana University Melvin and Bren Simon Comprehensive Cancer Center), Miguel Á. Sanz(Instituto de Investigación Sanitaria La Fe), Donald Small(Sidney Kimmel Comprehensive Cancer Center), Gunnar Juliusson(Lund University), Alexander E. Perl(University of Pennsylvania), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Michele Baccarani(University of Bologna), Maria R. Baer(University of Maryland, Baltimore), Harry P. Erba(Michigan Center for Translational Pathology), Amelia Langston(CancerCare Manitoba), Karen Yee(University Health Network), Arnon Nagler(Sheba Medical Center), Lucy A. Godley(University of Chicago), Giovanna Meloni(Sapienza University of Rome), Richard M. Stone(Dana-Farber Cancer Institute), Lothar Tremmel, Sergio Amadori(Polyclinic Medical Center), Anjali S. Advani(Cleveland Clinic), Mark R. Litzow(Mayo Clinic in Arizona), Debra M. Bensen-Kennedy, Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Takashi Sato(Kitasato University), W Wiktor-Jędrzejczak(Medical University of Warsaw), Ian D. Lewis, Stephen H. Petersdorf(Fred Hutch Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Dan Douer(Memorial Sloan Kettering Cancer Center), Martin S. Tallman(Memorial Sloan Kettering Cancer Center)
Cited by 32
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k